Immunosuppressive drug (%)
|
Yes
|
26 (100.0)
|
11 (100.0)
| |
No
|
0 (0.0)
|
0 (0.0)
| |
HTLV-1 b (%)
|
Yes
|
8 (30.8)
|
8 (80.0)
| |
No
|
18 (69.2)
|
2 (20.0)
|
0.011
|
HIV c (%)
|
Yes
|
11 (42.3)
|
7 (70.0)
| |
No
|
15 (57.7)
|
3 (30.0)
|
0.264
|
Neoplasms (%)
|
Yes
|
26 (100.0)
|
11 (100.0)
| |
No
|
0 (0.0)
|
0 (0.0)
|
–
|
Upcoming or current organ transplant (%)
|
Yes
|
26 (100.0)
|
11 (100.0)
| |
No
|
0 (0.0)
|
0 (0.0)
|
–
|
Diabetes mellitus (%)
|
Yes
|
26 (100.0)
|
11 (100.0)
| |
No
|
0 (0.0)
|
0 (0.0)
|
–
|
End-stage renal disease (%)
|
Yes
|
26 (100.0)
|
11 (100.0)
| |
No
|
0 (0.0)
|
0 (0.0)
|
–
|
Peripheral or unexplained eosinophilia (%)
|
Yes
|
25 (96.2)
|
10 (90.9)
| |
No
|
1 (3.8)
|
1 (9.1)
|
0.512
|
Drug-drug interaction with prescribed therapy, where patient taking at least 1 other prescription medication (%)
|
Yes
|
3 (11.5)
|
4 (36.3)
| |
No
|
9 (34.6)
|
2 (18.2)
| |
Not applicable
|
14 (53.8)
|
5 (45.5)
|
0.272
|
Country of birth (%)
|
Yes
|
20 (76.9)
|
11 (100)
| |
No
|
6 (23.1)
|
0 (0)
|
0.151
|